Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
about
Genetics of psoriasis and pharmacogenetics of biological drugsAnti-TNF agents for paediatric psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAnti-TNF agents for paediatric psoriasisEmerging therapies for the treatment of psoriasisThe origin and role of innate lymphoid cells in the lungTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesTargeting Th17 Cells with Small Molecules and Small Interference RNAA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewMaking the next steps in psoriatic arthritis management: current status and future directionsScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseReview: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyondNew era of biologic therapeutics in atopic dermatitisJakpot! New small molecules in autoimmune and inflammatory diseasesDiversity of IL-17-producing T lymphocytesStructure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signalingCrystal structures of interleukin 17A and its complex with IL-17 receptor AManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisNew targets in psoriatic arthritisEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesDevelopment of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to SkinTransient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cellsRationale and early clinical data on IL-17 blockade in psoriasis.Biologic agents in nail psoriasis: efficacy data and considerations.Anti-IL-17 phase II data for psoriasis: A review.First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasisCounter-regulation of T cell effector function by differentially activated p38.Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapyEarly tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.IL-6 as a druggable target in psoriasis: focus on pustular variants.New insights of T cells in the pathogenesis of psoriasisIL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.Risk of cardiovascular disorders in psoriasis patients: current and future.Clinical associations of serum interleukin-17 in systemic lupus erythematosus.Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.
P2860
Q21284816-4B1D802C-6081-4A6E-8B94-3DDBD2E5F5C7Q24187673-B8197CDD-C779-467F-9A5B-5FDFA14C6DCCQ24188334-E7A481AE-9286-4C80-A4C1-6F33C911E5EDQ24201907-ADA0D7CB-0667-4336-968A-849D0A88068BQ24605738-BB78040B-8978-4ADC-A253-0D972FC45EA5Q26740079-6A9C849E-A46F-4BE5-B687-FCA1BB37E0A7Q26764867-5A15DEF7-BAC6-4F4D-8644-6740507D83F0Q26770523-1275DE37-6734-4B91-964A-54D9D9308319Q26771682-33BC4233-1A51-42CB-839E-FF8F02649EABQ26771785-746E3392-5003-461A-AAED-01DB8046F45FQ26774874-DF65D2BF-3222-4D16-969D-7E8BBE1B7A79Q26783506-2F3C275F-4D57-4658-98A8-589E2A802DE0Q26798209-C7F8976C-EE4B-446C-B6EE-CD3187052A92Q26800937-B21B2C59-172E-4E01-BB4F-443EF66248AAQ26801173-705F9C42-B8A1-4BB5-AA4B-A1C66BC012E7Q26991709-A74A2145-43DC-401C-AC1A-83E17CA1D2BCQ27001941-C8CB6ABB-79DD-462B-8D79-1E30DA54CDE8Q27001957-CE666EAC-0FC8-47FB-83E0-31C806084160Q27010199-4434631D-35C9-4F04-8327-101652CD17ABQ27683721-C364931A-C258-478F-B851-06E3DCEFF1BAQ27684681-1C638C77-5C0D-424D-99F8-D4484BCF93B4Q27693878-820B538E-F2BB-4256-A662-3BA4BC56D9B6Q28069592-5E900253-F873-4C8D-87C3-53FD25B80FBBQ28076496-9039C37F-5737-4D73-B13E-EBBB48B0EEB1Q28550171-410C3412-0240-42D9-B3D9-64D6C6EC6AAEQ28829881-C42BB0AF-5107-4669-BCB4-8D7D4034FB21Q30658185-C70B11B4-819E-41ED-8F59-FE769C907765Q30683539-E35073E1-BEAA-483D-BC65-11A9BCCED1B3Q30760301-F3C69ABB-BD99-4F9A-AEE3-61AD49CF6D83Q33593625-311738E9-6F18-46CA-BC22-26C7ED4F11B3Q33702970-DD60AB6B-C28F-4F6D-9699-DA1FA4175599Q33785074-97FF1BD1-C90F-44F9-BB2F-613D3741978FQ33969217-EE62024B-8E19-486B-9D95-76116EF9F7E7Q34003280-EE2651F1-1537-472F-87B0-BC3C6BFE2FE6Q34043846-F5AF22D7-D5A4-4878-AB03-140915F93139Q34082705-3F714E82-EFC0-4879-AADF-F4D2278454D6Q34130313-76EB7802-4070-4A76-861D-6C29576E0D09Q34323212-B0BA67E5-0221-40C9-8A31-42E2A343C699Q34365880-34BDDA62-CD3E-4200-86C9-13DD2C2536D1Q34380190-61E18B5D-42A3-4BD5-9476-6030C69981E3
P2860
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
description
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 March 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@en
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@nl
type
label
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@en
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@nl
prefLabel
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@en
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
@nl
P2093
P356
P1476
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
@en
P2093
Alan Menter
Craig Leonardi
Elizabeth H Z Thompson
Girish Aras
Gregory Kricorian
James G Krueger
Jean-Paul Ortonne
Scott Baumgartner
P304
P356
10.1056/NEJMOA1109017
P407
P577
2012-03-01T00:00:00Z